Multiple Sclerosis (MS) and Neuroimmunology

URMC Neurology Research

Scope of Research: Multiple Sclerosis and other Immune Disorders of the Central Nervous System

The current focus is cutting-edge clinical research and experimental therapeutics of multiple sclerosis.

  • Clinical research assessing novel immunotherapies targeted at multiple steps in the pathogenesis of MS lesions
  • Clinical research evaluating new symptomatic therapies
  • Clinical research studies of fatigue, cognitive dysfunction, and other aspects of MS

References

Rudick RA, O'Connor PW, Polman CH, Goodman AD, et al. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients. Ann Neurol 2010;68(3):304-310.

Goodman, AD; Rossman, H; Bar-Or, A; Miller, A; Miller, DH; Schmierer, K; Lublin, F; Khan, O; Bormann, NM; Yang, M; Panzara, MA; Sandrock, AW; GLANCE Investigators. "GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study." Neurology 3 (2009): 806-12. View PubMed Reference

Goodman AD; Brown TR; Drupp LB; Schapiro RT; Schwid SR; Cohen R; Marinucci LN; Blight AR; Fampridine MS-F203 Investigators. "Sustained-release oral fampridine in multiple sclerosis: a randomized double-blind, controlled trial." Lancet. 28 (2009): 697-8. View PubMed Reference

Goodman AD; Brown TR; Cohen JA; Krupp LB; Schapiro R; Schwid SR; Cohen R; Marinucci LN; Blight AR; . "Dose comparison trial of sustained-release fampridine in multiple sclerosis." Neurology. 2008; 71(15):1134-41. Epub 2008 Jul 30. View PubMed Reference

Andrew D. Goodman, M.D., Unit Chief
Andrew_Goodman@urmc.rochester.edu
(585) 275-7854